Many attempts have been made to find genetic abnormalities inducing carcinogenesis after the development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor targeting EGFR in lung cancer. New target therapies have been already commercialized and studied along with the recent discovery of gene rearrangement involved in the carcinogenic process of non-small cell lung cancer. This study aims to investigate anplastic lymphoma kinase, c-ros oncogene 1, and receptor tyrosine kinase, in particular.
Anplastic Lymphoma Kinase (ALK)

Mechanism and epidemiology
Lung cancer is known to occur because ALK is expressed due to the gene rearrangement of echinoderm microtubuleassociated protein like-4-ALK (EML4-ALK) 1 . The gene rearrangement occurs relatively lesser than epidermal growth factor receptor (EGFR) mutation in ALK-positive lung cancer, and detected in 3−5% of non-small cell lung cancer (NSCLC) patients according to recent studies 2, 3 . Although the prevalence of ALK-positive lung cancer varies between 2% and 13% according to several previous studies, this is attributable to the pre-selections of clinical and demographic character-www.e-trd.org 6 and 42 weeks. Disease control rate were 85.0% in the 6th week and 73.7% in the 12th week. More than 90% of patients showed decreases in tumor size to some degree. An abnormal response profile to orally given crizotinib was generally safe and excellent in tolerability. The most common adverse effect (AEs) are visual disturbances and gastrointestinal-related problems in patients with ALK-positive lung cancer. Nausea, diarrhea, vomiting and constipation ranged from mild to moderate in terms of severity. The incidence of severe and serious AE and abnormal laboratory test values was relatively lower in crizotinib therapy. Those patients could be controlled through administration suspension, dose reduction, and/or standard medical therapy. The most frequently reported treatmentassociated serious AE was interstitial pneumonia in 2 patients (1.7%) with ALK-positive NSCLC.
Diagnosis 3
The domestic use of crizotinib has been approved in ALK fluorescence in situ hybridization (FISH) positive NSCLC since last year. Break-apart FISH is the only diagnostic standard in EML4-ALK translocation. Since FISH is difficult and expensive in interpretation, immunohistochemical staining has been attempted for diagnosing ALK-positive NSCLC. Although some studies have suggested that strong positive (3+) in immunohistochemical staining is highly likely to be FISH positive ALK, this test method could not replace test results. Since immunohistochemical staining is cost-effective and convenient way to perform, it is commonly used for diagnosing ALK-positive patients.
Mechanism 2
The use of ALK inhibitors for definite period of time showed tolerability like EGFR-tyrosine kinase inhibitor (TKI). New mutations including C1156Y and L1196M are detected in ALK kinase in biopsy performed in lung cancer recurrent patients administered with ALK inhibitors 5 . The tolerance mechanism of those mutations resembles that of imatinib used in recombination of BCR-ABL rather than T790M mutation which is the tolerance mechanism of EGFR-TKI. Mutation was observed in 20% to 40% of patients, and the amplification of ALK gene was detected in 5% to 20% of patients in case of resistance to ALK inhibitors. The recombination of ALK gene disappeared when tolerability developed in some studies, implying that K-RAS proliferates selectively in cancers with various genetic mutations. In this case, ALK signaling system is not depended upon, since the addiction on ALK vanishes. Thus, the use of drugs on other signaling system could be considered to overcome tolerance. When gene mutation and an increase in the number of copies develop, the mechanism of resistance to ALK inhibitors relays on ALK signaling system. Therefore, patients with this resistance require stronger inhibitors than currently commercialized crizotinib. Recently investigated LDK378 (Novartis), AP26113 (ariad), and CH5424802 (chugai) are anticipated to be effective in crizotinib resistant mutation, and the outcome of currently performed clinical trials are look forward to acquiring. 
